At present, around 59 million adults worldwide have diabetes, about 64 million are diagnosed with heart failure, and ...

We knew that GLP-1 drugs like Ozempic and Wegovy did more than just help control type 2 diabetes and aid weight loss, but the ...

Novo Nordisk has launched its blockbuster diabetes drug Ozempic in India, pricing the starter dose at ₹8,800 per month (₹2,200 per week), positioning it as a competitor to Eli Lilly's Mounjaro (priced ...

Looking to expand its footprint in the booming glucagon-like peptide (GLP-1) market, Danish drugmaker Novo Nordisk has ...

But even as Ozempic enters India, there is a growing sense globally that Novo may have already lost the obesity drug war to Mounjaro, Eli Lilly’s blockbuster that has become India’s top-selling drug ...

A weight loss drug dubbed the "triple G" drug for its effectiveness in mimicking three hunger-regulating hormones showed promising results in new data released Thursday by its maker, Eli Lilly.

We never know what demons other people are fighting, even if we think we see their problems from the outside. Those who ...

As GLP-1 therapies gain momentum globally and in India, Novo Nordisk’s launch of Ozempic signals a deeper push to capture the ...

In an interview, Novo Nordisk India’s managing director Vikrant Shrotriya discusses the launch of Ozempic, the company’s ...

Obesity is a big driver of healthcare spending in South Africa, yet most medical schemes still limit cover for effective ...

I ordered Mounjaro, one of the so-called 'miracle' weight-loss injections that have been dominating headlines. Within weeks, ...

Ozempic has hit the Indian market and will be available at Rs 2,200 per week. But did you know that there are alternatives ...